

Substitute Form PTO-1449 (Modified)  <b>Information Disclosure Statement by Applicant</b> (Use several sheets if necessary)  (37 CFR §1.98(b))	U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. 06275-0435US1	Application No. 10/521,325
		Applicant Bonnert et al.	
		Filing Date August 15, 2005	Group Art Unit 1626

**U.S. Patent Documents**

Examiner Initial	Desig. ID	Document Number	Publication Date	Patentee	Class	Subclass	Filing Date If Appropriate
	1	2006-0111426	05/25/2006	Bonnert et al.			
	2	2008-0249110	10/09/2008	Bonnert et al.			
	3	2006-0264444	11/23/2006	Bonnert et al.			
	4	2008-0027092	01/31/2008	Bonnert et al.			
	5	2008-0051586	02/28/2008	Keegan et al.			

**Foreign Patent Documents or Published Foreign Patent Applications**

Examiner Initial	Desig. ID	Document Number	Publication Date	Country or Patent Office	Class	Subclass	Translation	
							Yes	No
	6	WO 01/032621	05/10/2001	WIPO			Abstract	
	7	WO 03/101961	12/11/2003	WIPO				
	8	WO 03/101981	12/11/2003	WIPO				
	9	WO 2004/007451	01/22/2004	WIPO				
	10	WO 2004/106302	12/09/2004	WIPO				
	11	WO 2005/019171	03/03/2005	WIPO				
	12	WO 2005/040114	05/06/2005	WIPO				
	13	WO 2005/054232	06/16/2005	WIPO				
	14	WO 2006/075139	07/20/2006	WIPO				
	15	WO 2007/138282	12/06/2007	WIPO				

**Other Documents (include Author, Title, Date, and Place of Publication)**

Examiner Initial	Desig. ID	Document
	16	Morissette et al., "High-throughput crystallization: polymorphs, salts, co-crystals and solvates of pharmaceutical solids", <i>Advanced Drug Delivery Reviews</i> 56:275-300 (2004)
	17	Patani and LaVoie, "Bioisosterism: A Rational Approach in Drug Design", <i>Chem Rev.</i> 96:3147-3176 (1996)
	18	
	19	
	20	

Examiner Signature	Date Considered
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	